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Vaccinia virus (VV) K1L is a host-range gene and encodes a protein comprised of six ankyrin repeats (ANKs). We showed here that a large
portion of the K1L protein, except ankyrin repeat 1 (ANK1) and C-terminal halves of ANK2 and ANK3, can be deleted or substituted with an
unrelated ANK with no adverse effect on VV replication in human HeLa cells. In contrast, only ANK4 and ANK6 can be mutated without
impairing VV replication in rabbit RK13 cells. The growth rate of VV in HeLa cells was reduced differentially by substituting phenylalanine 82 or
serine 83 of ANK2 and abolished completely by substituting both residues. These substitutions, however, did not affect K1L's ability to bind
ACAP2, a GTPase-activating protein for ARF6. Our data support the hypothesis that surface residues of a few consecutive K1L ANKs mediate
the host-range function by interacting with protein factors that are distinct from ACAP2.
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Vaccinia virus (VV) is the prototypical member of the
poxvirus family and served as an effective vaccine for smallpox
during its global eradication campaign (Moss, 2001). The origin
and the natural host of VV are not entirely clear, but the wild-
type VV strains are capable of replicating in a very broad range
of cell lines of both avian and mammalian origins. VV strains
with a more restricted host-range, notably the modified vaccinia
virus Ankara (MVA) and NYVAC, have also been derived from
the wild-type strains through empirical process or targeted gene
deletions (Carroll and Moss, 1997; Tartaglia et al., 1992). MVA
and NYVAC replicate efficiently in primary chicken embryo
fibroblasts but abortively in most mammalian cell lines. They
are highly attenuated in mammalian hosts and considered as a
potential safe replacement for the currently licensed smallpox
vaccine (Belyakov et al., 2003). They have also been used
extensively as the vaccine vectors for other infectious diseases⁎ Corresponding author. Fax: +1 210 567 6612.
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doi:10.1016/j.virol.2006.05.032and cancer (Sutter and Staib, 2003). Their immunogenicities,
however, are reduced compared to replication-competent VV
strains, typically requiring booster doses to be administered to
elicit optimal immune responses (Earl et al., 2004; Kaufmann
and McMichael, 2005; Spearman, 2006).
For MVA, the genetic basis of its host-range restriction to
avian cells is ill-defined (Wyatt et al., 1998), but, for NYVAC,
the targeted deletion of two VV genes, K1L and C7L, is
presumably the cause. VV mutants with deletion in both K1L
and C7L genes replicate abortive in most human cell lines and
the rabbit kidney RK13 cells (Drillien et al., 1981; Gillard et al.,
1986; Perkus et al., 1990). The replication defect of the mutants
in human cells can be complemented by either K1L or C7L or
the cowpox virus CP77 gene, while the defect in RK13 cells can
be complemented by either K1L or CP77 but not by C7L
(Gillard et al., 1986; Perkus et al., 1990; Ramsey-Ewing and
Moss, 1996). The host restriction of the mutants occurs at the
translation of intermediate stage viral mRNA in human HeLa
cells (Hsiao et al., 2004), while it occurs at the translation of
early stage viral mRNA in RK13 cells (Ramsey-Ewing and
Moss, 1996). However, the exact nature of the host restriction in
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C7L overcome the host restriction remain elusive today
(McFadden, 2005).
Both CP77 and K1L contain multiple ankyrin repeats
(ANKs), a common 33-residue protein motif that has been
found in proteins as different as cytoskeletal organizers, cyclin-
dependent kinases (CDK) inhibitors and signal transduction and
transcriptional regulators (Mosavi et al., 2004; Sedgwick and
Smerdon, 1999). ANK represents a structural scaffold for
mediating protein–protein interactions (Sedgwick and Smerdon,
1999). The three-dimensional structures of the ANKs-con-
taining proteins show very regular and conserved secondary and
tertiary structure. Each repeat forms a structural unit, which
consists of a β-hairpin, two antiparallel α-helices followed by a
loop. The adjacent repeats are packed via hydrophobic
interactions to form an elongated L shape structure with a
large solvent-accessible surface. Despite this conserved struc-
tures, different ANKs-containing proteins interact specifically
with their binding partners by containing variable surface
residues in the repeats and by stacking different numbers of the
repeats in one protein (Sedgwick and Smerdon, 1999).
Based on the studies of cellular ANKs-containing proteins,
we hypothesized that the surface residues of a few consecutive
ANKs of K1L mediate the host-range function by interacting
with protein factors. To test our hypothesis and gain some insight
into the molecular basis of the host-range gene function, we
systematically examined all K1L ANKs for their contributions
towards VV replication in both human HeLa cells and rabbit
RK13 cells and towards the binding with ACAP2, the humanFig. 1. Construction of recombinant VVs that depend on K1L's host-range function
construction and genomic organization of vK1L−C7L− and vK1L-WT. vK1L−C7L− w
vTF7.3 with the transient dominant selection method. The exact positions of the delet
genome sequence (accession number AY243312). The neighboring WR ORFs are
homologous recombination of vK1L−C7L− and the plasmid pK1L-V5-GFP, which
protein (GFP). P11 indicates the VV promoter that normally regulates late expression
of K1L proteins by vK1L-WT in RK13 cells. RK13 cells were infected with vK1L-
infection (hpi), the level of K1L proteins was determined by Western blot with a mono
determined by Bradford protein assay was analyzed. The size of the molecular weighomolog of a rabbit protein previously identified to bind K1L
(Bradley and Terajima, 2005). Our data support the hypothesis
that surface residues of a few consecutive K1L ANKs mediate
the host-range function by interacting with protein factors that
are distinct from ACAP2. It also demonstrates that the growth
rate of VV vectors in human cells can be modulated by genetic
engineering of the host-range genes.
Results
Construction of K1L mutant VVs
VV K1L and C7L provide an equivalent function for VV to
replicate productively in many human cell lines. Therefore, to
assess the effect of K1L mutations on VV replication in human
cell lines as well as rabbit RK13 cells, we constructed a
recombinant VV with neither K1L nor C7L genes (named
vK1L−C7L−) as the parental virus for all the K1L mutants. As
expected from previous studies of similar mutants (Perkus et al.,
1990), vK1L−C7L− replicated abortively in both RK13 and
human HeLa cells but robustly in monkey VERO cells (data not
shown). Restoring to vK1L−C7L− the coding sequences for a
K1L with a C-terminal V5 epitope tag and an adjacent green
fluorescence protein (GFP) also restores the normal host-range
of the virus (referred as vK1L-WT or WT hereafter). The
epitope-tagged K1L protein (K1L-V5) was expressed from the
natural K1L promoter by vK1L-WT and displayed the kinetics
of synthesis of VV early gene (Fig. 1). The GFP was expressed
from the widely used P11 promoter, which normally regulatesfor replication in RK13 and human cell lines. (A) Schematic illustration of the
as constructed by sequentially removing the K1L and C7L genes from VV strain
ions are indicated by the corresponding nucleotide numbers of the complete WR
indicated by their numerical nomenclature only. vK1L-WT was constructed by
encodes the K1L with a C-terminal V5 epitope tag and the green fluorescence
of the gene encoding the 11K protein (WR F18R). (B) The temporal expression
WT or wild-type WR at a MOI of 10 PFU per cell. At the indicated time after
clonal antibody against the V5 epitope tag. The same amount of total proteins as
ht marker in kilodaltons is shown on the left.
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(WR F18R). Various VVs encoding mutated K1L proteins were
constructed similarly in VERO cells, where all mutants
replicated as efficiently as the WT.
C-terminal residues 193 to 277 of K1L can be deleted with no
adverse effect on VV replication in HeLa cells
The SMART (Simple Modular Architecture Research Tool)
program predicts that the majority of the 285 amino acids
(residue 29 to 222) of the K1L protein form six ankyrin repeats
(ANKs) (Letunic et al., 2004). The remaining N-terminal 28 and
C-terminal 62 amino acids have no discernible motif. As ANK
is a modular protein building block and anywhere from 2 to 33
ANKs were found in a single protein (Mosavi et al., 2004), we
first determined whether some of the K1L ANKs were
redundant for the host-range function. We constructed seven
K1L deletion mutants, each of which has a precise deletion at
one of the ANKs or the C-terminal non-ANK sequence (Fig.
2A). The mutants with a deletion at any one of the five N-
terminal ANKs (D1, D2, D3, D4 and D5 mutants) failed to
replicate in HeLa cells, but the mutants with a deletion at
ankyrin repeat 6 (ANK6) (D6 mutant) or the C-terminal non-
ANK sequence (D7 mutant) replicated as efficiently as the WT
did, at either the low or high multiplicity of infection (MOI)
(Fig. 2B).
All deletion mutants expressed K1L proteins at a reduced
level in both HeLa cells and the permissive VERO cells (Fig. 2C
and data not shown). D1 to D5 mutants were unable to express
GFP in HeLa cells (Fig. 2D), indicating that their replications
were blocked before the onset of VV late protein synthesis. D6
and D7 mutants, however, expressed GFP in infected HeLa cells
and formed GFP-positive plaques that were similar in size to
those formed by the WT (Fig. 2D), confirming that residues 193
to 277 of K1L were not required for VV replication in HeLa
cells.
Substituting ANK4, ANK5 and the N-terminal halves of ANK2
and ANK3 with an unrelated synthetic ANK has no adverse
effect on VV replication in HeLa cells
As the deletions at the five N-terminal ANKs might impair
K1L function through indirect effect on protein structure, we
further assessed the importance of the K1L ANKs to the host-
range function by substituting each K1L ANK with an
unrelated ANK. The unrelated ANK that was chosen for the
substitution was a synthetic ANK previously designed based on
the consensus sequence of many cellular ANKs and was
known to fold into the typical ANK structure (Kohl et al.,
2003) (PDB accession number 1MJ0, Fig. 3A). Initially, we
substituted the entire K1L ANK2 with the synthetic ANK (Fig.
3A). This substitution (S2) resulted in the change of 17
residues, the majority of which are not conserved between
different ANKs and typically contribute to specific protein–
protein interactions (Kohl et al., 2003). The S2 substitution
impaired VV replication in HeLa cells, as shown by one-step
viral growth curve (Fig. 3B). Furthermore, a smaller substitu-tion at only the C-terminal half of ANK2 (S2C) had the same
negative effect. In contrast, the substitution at only the N-
terminal half of ANK2 had no adverse effect on VV replication
in HeLa cells (Fig. 3B).
We went on and performed similar substitution studies on
other K1L ANKs (Fig. 4). Identical to ANK2, the substitution at
the N- and C-terminal halves of ANK3 (S3N and S3C) also
displayed different effect on VV replication in HeLa cells. The
S3C substitution impaired VV replication, while S3N substitu-
tion had no adverse effect. No such distinction was found for
ANK1, where the substitutions at either the N- or C-terminal
half (S1N and S1C) abolished VV replication in HeLa cells, or
for ANK4 and ANK5, where no substitution (S4N, S4C, S5N or
S5C) had any adverse effect on VV replication in HeLa cells
(Fig. 4).
In the nonpermissive HeLa cells, S2C and S3C substitution
mutants expressed a wild-type level of K1L proteins (Figs. 3C
and 4C), indicating that the block on their replication occurs
after VV early protein synthesis. S1N and S1C substitution
mutants, however, expressed a lower level of K1L proteins (Fig.
4C). This was not due to a host restriction on their early protein
synthesis, as they also expressed a reduced level of K1L
proteins in the permissive VERO cells (Fig. 4C). Interestingly,
S2N, S3N and S5C substitution mutants also expressed a
reduced level of K1L proteins in all cell types tested (Fig. 4C),
indicating that a low K1L protein level does not necessarily
cause the host-range defect.
S1N, S1C, S2C and S3C mutant viruses formed plaques
with the wild-type size in the permissive VERO cells (Fig.
4E and data not shown), but they failed to form GFP-
positive plaques in HeLa cells (Figs. 3D and 4D), indicating
that their replications in HeLa cells were blocked before the
synthesis of viral late proteins. All other substitution mutants
were able to form GFP-positive plaques in HeLa cells, with
a size that is not significantly different from the WT (Figs.
3D and 4D).
VV growth rate in HeLa cells can be modulated by substituting
phenylalanine 82 and/or serine 83 of ANK2
To map the exact residues of ANK2 that mediate the host-
range function, we introduced increasingly smaller substitutions
into ANK2 (Fig. 5A). As substituting nine residues at the C-
terminal half of ANK2 (S2C) abolished viral replication in
HeLa cells, we initially constructed three mutant viruses
(S2C#1, S2C#2 and S2C#3), each of which contained
substitutions at three amino acids. While S2C#1 and S2C#3
mutants replicated as efficiently as the WT did in HeLa cells,
S2C#2 failed to replicate in HeLa cells (Fig. 5B). Among the
three residues that were substituted in S2C#2, we suspected that
the leucine 85 to alanine substitution to be of little consequence.
Indeed, the substitution of only leucine 85 to alanine (S2C#4)
had no adverse effect on VV replication in HeLa cells.
However, an additional phenylalanine 82 to lysine substitution
(S2C#5) greatly reduced VV growth rate in HeLa cells, while an
additional serine 83 to histidine substitution (S2C#6) reduced
the growth rate to a lesser degree (Fig. 5B). Neither substitution
Fig. 2. C-terminal residues 193 to 277 of K1L can be deleted with no adverse effect on VV replication in HeLa cells. (A) Schematic illustration of the K1L proteins
encoded by the K1L deletion mutants. The residues that were deleted from each mutant are indicated by their first and last residue numbers in the broken line segment.
The growth phenotypes of the mutants in HeLa cells are summarized on the right. (B) Growth curves of K1L deletion mutants in HeLa cells at high (5 PFU/cell) and
low (0.01 PFU/cell) MOIs. Virus yields at 0, 12 and 48 h post-infection (hpi) were determined by plaque assay on the permissive VERO cells. The growth curves of
D1, D3 and D5 are identical to those of D2 and D4 and not shown for clarity. The standard deviation from two replicate experiments was also shown. (C) The steady-
state level of K1L proteins in HeLa cells that had been infected with K1L deletion mutants. HeLa cells were infected at a MOI of 5 PFU/cell. The level of K1L proteins
at 8 hpi was determined byWestern blot with a monoclonal V5 antibody. The same amount of total proteins as determined by Bradford protein assay was analyzed. (D)
D6 and D7 mutants form normal GFP-positive plaques in HeLa cells. HeLa cells were infected at a MOI of 0.01 PFU/cell. At approximately 36 hpi, GFP-expressing
cells were visualized with an inverted fluorescence microscope using a 10× objective. The same exposure time was used to photograph different samples. The obtained
color images were converted to grayscale and GFP is shown in white. Not shown are the images of D1, D2, D3 and D5 mutants, which are identical to that of D4.
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of both residues (S2C#2) did, suggesting that phenylalanine 82
and serine 83 together contribute to VV replication in HeLa
cells.
All the substitution mutants expressed K1L proteins at the
wild-type level in HeLa cells (Fig. 5C). The electrophoretic
mobility of the K1L protein was altered significantly by theS2C#1 and S2C#3 substitutions. This alteration was not due to
any unintended mutation introduced during virus construction
process, as re-constructing S2C#1 and S2C#3 mutants with re-
sequenced transfer plasmids yielded the same result (data not
shown). In HeLa cells, consistent with their respective growth
rates, S2C#2, S2C#5 and S2C#6 displayed different abilities
to synthesize VV late proteins, as indicated by the expression
Fig. 3. Substituting the N-terminal half of K1L ANK2 with an unrelated synthetic ANK has no adverse effect on VV replication in HeLa cells. (A) The amino acid
sequence of K1L ANK2 is shown in an alignment with the synthetic ANK sequence from 1MJ0. The actual and schematic representation of the synthetic ANK
structure is shown above the alignment with the secondary structure components labeled. The amino acids that were substituted into each K1L mutant were shown
below the alignment. The nonconservative and conservative amino acid changes are shown in regular and italic, respectively. The residue numbers of the first and last
residue of each ANK are shown in the bracket. The growth phenotypes of the mutants are summarized on the right. (B) One step growth curves of K1L ANK2
substitution mutants in HeLa cells. Virus yields were determined by plaque assay on VERO cells. The standard deviation from two replicate experiments was also
shown. (C) The steady-state level of K1L proteins in HeLa cells that had been infected with ANK2 substitution mutants for 8 h. The experimental condition was
identical to that described in Fig. 2C. (D) S2N substitution mutant forms normal GFP-positive plaque in HeLa cells. The experimental condition was identical to that
described in Fig. 2D.
224 X. Meng, Y. Xiang / Virology 353 (2006) 220–233of GFP (Fig. 5D). S2C#2 failed to form GFP-positive plaques,
S2C#5 was only able to form tiny foci consisted of a few
GFP-expressing cells and S2C#6 formed plaques with areduced GFP intensity, indicating that their late protein
synthesis and cell-to-cell spread were reduced to different
degrees.
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on viral replication in RK13 cells
All K1L mutant viruses were also tested for their abilities to
replicate in RK13 cells. Identical to their respective phenotypes
in HeLa cells, all mutants that were defective at replicating in
HeLa cells failed to replicate productively in RK13 cells, and
the mutants with a deletion at ANK6 (D6) or substitutions at
ANK4 (S4N and S4C) replicated as efficiently as the WT did in
RK13 cells (data not shown). However, most other K1L
mutants displayed distinctly different phenotypes in RK13 cells.
The mutant with a deletion at the C-terminal non-ANK
sequence (D7) formed only small foci with a few GFP-
expressing cells and achieved a smaller amplification in titer in
RK13 cells (Fig. 6). The phenotypic differences were even
greater for the mutants with substitution at N-terminal halves of
ANK2 and ANK3 (S2N, S3N), at phenylalanine 82 or serine 83
of ANK2 (S2C#5 and S2C#6), and at ANK5 (S5N, S5C). None
of these mutants achieved any amplification in titer when
propagating on RK13 cells (Fig. 6A).Fig. 4. Substituting ANK4, ANK5 and the N-terminal half of ANK3 with an unrelate
amino acid sequences of the N-terminal five ANKs of K1L are shown in an alignm
substituted into each mutant are shown below the alignment, with the nonconservativ
phenotypes of the mutants in HeLa cells are summarized. (B) Growth curves of K1L su
S1N, S1C are similar to those of S3C, and the growth curves of S3N are similar to th
proteins in HeLa or VERO cells that had been infected with K1L substitution mutan
(D) S3N, S4N, S4C, S5N and S5C mutants form normal GFP-positive plaques in H
(E) S1N, S1C and S3C mutants form normal plaques in permissive VERO cells.For mutants that failed to replicate in both HeLa and RK13
cells, their K1L protein levels were lower in RK13 cells than in
HeLa cells. This is most evident for S3C and S2C#2 mutants,
which expressed the wild-type level of K1L proteins in HeLa
cells but a reduced level of K1L proteins in RK13 cells
(compare Figs. 4C, 5C and 6B), indicating that their early viral
protein synthesis was partially blocked in RK13 cells. Most of
the mutants that failed to replicate in RK13 cells also failed to
express GFP. However, the S5N substitution mutant was able to
express a low level of GFP that was more evident at high MOI,
indicating that its late viral protein synthesis was only partially
blocked in RK13 cells.
K1L interacts with human ACAP2, but there is no correlation
between ACAP2 binding and the host-range function
K1L was previously reported to interact with the rabbit
homolog of human ACAP2 (Bradley and Terajima, 2005), a
GTPase-activating protein (GAP) for the small GTPase ARF6
(Jackson et al., 2000). ACAP2 shares approximately 50%d synthetic ANK has no adverse effect on VV replication in HeLa cells. (A) The
ent with the synthetic ANK sequence from 1MJ0. The amino acids that were
e and conservative changes shown in regular and italic, respectively. The growth
bstitution mutants in HeLa cells at the high and lowMOIs. The growth curves of
ose of S4C. They were not shown for clarity. (C) The steady-state level of K1L
ts for 8 h. The experimental condition was identical to that described in Fig. 2C.
eLa cells. The experimental condition was identical to that described in Fig. 2D.
The plaques were visualized at 48 hpi with crystal violet staining.
Fig. 4 (continued).
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for ARF6 (Jackson et al., 2000). To determine whether K1L is
capable of interacting with ACAP2 or ACAP1, we ectopically
expressed V5-tagged K1L protein (K1L-V5) together with
either Flag-tagged ACAP1 protein (ACAP1-Flag) or ACAP2
protein (ACAP2-Flag) and performed co-immunoprecipitation
assay (Fig. 7A). Either anti-V5 or anti-Flag monoclonal
antibody precipitated down both K1L-V5 and ACAP2-Flag
proteins from human 293T cells that expressed both proteins. Incontrast, anti-V5 and anti-Flag antibody precipitated down
K1L-V5 and ACAP1-Flag, respectively, but not both, from
293T cells that expressed both proteins, indicating that K1L
specifically interacts with ACAP2 but not ACAP1.
To determine whether ACAP2 interaction is essential for
K1L's host-range function, we examined whether the K1L
proteins of the WTand mutant viruses were able to interact with
the endogenous ACAP2 proteins in HeLa cells. The K1L
proteins from infected HeLa cells were immunoprecipitated,
Fig. 5. VV growth rate in HeLa cells can be modulated by substituting phenylalanine 82 or/and serine 83 of ANK2. (A) The amino acids that were substituted into each
mutant are shown below the alignment of K1L ANK2 with the synthetic ANK sequence of 1MJ0. (B) One-step growth curves of K1L substitution mutants in HeLa
cells. (C) The steady-state level of K1L proteins in HeLa cells that had been infected with ANK2 substitution mutants for 8 h. (D and E) GFP-positive plaques formed
by K1L substitution mutants in HeLa cells. The images of WT, S2C#1, S2C#2 and S2C#3 were obtained at 36 hpi, while those of S2C#4, S2C#5 and S2C#6 were
obtained at 48 hpi. All the images were photographed with the same exposure time. A small focus formed by S2C#6 was enlarged 2 times and shown with more
contrast.
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ACAP2 proteins with specific monoclonal antibodies (Figs. 7B
and C). Awild-type level of K1L proteins was precipitated from
cells infected by S2C, S2C#2, S2C#3, S3C, S4N, S4C or S5N
mutants, while a reduced amount of K1L proteins were
precipitated from cells that were infected by the remaining
K1L mutants, consistent with the steady-state level of K1Lproteins in cells that were infected by the respective mutants.
The WT K1L proteins were able to bring down the endogenous
ACAP2 proteins, indicating that K1L interacts with ACAP2
during viral replication. A similar amount of ACAP2 was also
brought down by the K1L proteins of S2C#2 mutant, which was
defective at replicating in HeLa and RK13 cells, demonstrating
that the three amino acid substitutions in S2C#2 disrupted
Fig. 6. Only ANK4 and ANK6 can be mutated with no adverse effect on viral replication in RK13 cells. (A) One-step growth curves of K1Lmutants in RK13 cells. (B)
The steady-state level of K1L proteins in RK13 cells that had been infected with K1L mutants for 8 h. (C) The expression of GFP under the control of VV late promoter
P11 by K1L mutants in RK13 cells at the high and low MOIs.
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ACAP2. A decreased amount of ACAP2 was brought down by
the K1L proteins of S2C and S2C#3 mutants. Furthermore, no
detectable amount of endogenous ACAP2 was brought down
by K1L proteins of the rest of K1L mutant viruses that were
tested. As S4N and S4C substitution mutants were able to
replicate in HeLa and RK13 cells as efficiently as the WT did,
the fact that their K1L proteins were unable to precipitate
ACAP2 suggests that K1L's interaction with ACAP2 may not
be essential for its host-range function in either HeLa or RK13
cells.
Discussion
K1L, C7L and CP77 were identified more than 10 years ago
as genes that are required for VV to replicate productively in
many in vitro cell lines (Gillard et al., 1986; Perkus et al., 1990;
Spehner et al., 1988). However, the exact nature of the hostrestriction in nonpermissive cells and the mechanisms by which
these host-range genes overcome the host restriction remain
elusive today. In this study, we provided the first comprehensive
structure–function analysis of K1L to gain some insight into the
molecular basis of the host-range function.
We found that a large portion of the K1L protein did not
contain any specific residue for supporting VV replication in
human HeLa cells. This includes ANK4, ANK5, ANK6 and the
C-terminal non-ANK residues. ANK6 and C-terminal non-
ANK residues are clearly not required, as they can be deleted
from K1L with no deleterious effect on VV replication in HeLa
cells. ANK4 and ANK5 may be required for maintaining the
appropriate K1L structure, as their deletion abolished viral
replication in HeLa cells. However, they can be functionally
substituted with an unrelated synthetic ANK. Each substitution
changed all but 2 or 3 residues of a 16-residues block.
Presumably, the substitution altered the surface residues of K1L
ANKs without changing the overall structure, as different
Fig. 7. K1L interacts with human ACAP2, but this interaction is not essential for K1L's host-range function. (A) HEK293T cells in 6-well plate were co-transfected
with 2 μg of a mammalian expression vector for K1L-V5 and 2 μg of a mammalian expression vector for ACAP1-Flag or ACAP2-Flag. Forty-eight hours after
transfection, the cells were lysed. The level of epitope-tagged proteins in the cell lysates was determined by Western blot with anti-V5 or anti-Flag antibody. The cell
lysates were precipitated with agarose conjugated with either anti-V5 or anti-Flag antibody. The levels of ACAP1-Flag, ACAP2-Flag and K1L-V5 proteins in the
precipitates were determined byWestern blot with anti-Flag and anti-V5 antibodies. (B and C). HeLa cells in 6-well plate were infected with the indicated K1L mutants
at a MOI of 10 PFU/cell. At 8 hpi, the cells were lysed. The level of ACAP2 protein in the cell lysates was determined by Western blot with a monoclonal antibody
against ACAP2. K1L proteins were immunoprecipitated from the cell lysates with agarose conjugated with anti-V5 antibody. The levels of ACAP2 and K1L proteins
in the precipitates were determined by Western blot with monoclonal antibody against ACAP2 and V5, respectively.
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that are unique. Therefore, if K1L supports viral replication in
HeLa cells by interacting with protein factors, ANK4 and
ANK5 do not contain any specific surface residues that could
contribute to this interaction. The finding that a large portion of
K1L is not essential for the host-range function in HeLa cells is
consistent with some previous findings on ligand binding by
cellular ANK proteins. Cellular ANK proteins often interact
with a ligand via a few of their multiple ANKs, with the rest of
the ANKs either playing a structural role or, as often is the case,
performing additional functions by interacting with other
ligands (Mosavi et al., 2004; Sedgwick and Smerdon, 1999).
For example, the human oncogenic protein Gankyrin, which
encodes seven ANKs, binds to cycline-dependent kinase 4
(CDK4) and retinoblastoma gene product (RB) via the N-
terminal 3 or 4 ANKs and the sixth ANK, respectively(Krzywda et al., 2004; Padmanabhan et al., 2004; Yuan et al.,
2004).
The region of K1L that was found to be essential for VV
replication in HeLa cells centers on a contiguous surface of a
typical ANK structure, consistent with a possible role in ligand
binding. Variable ANK residues at ANK1 and the C-terminal
halves of ANK2 and ANK3 were found to be essential for VV
replication in HeLa cells, while those at the N-terminal halves of
both ANK2 and ANK3 were not. Although the C-terminal
halves of consecutive ANKs are separated in primary sequence
by the N-terminal halves of the ANKs, they are positioned at the
same side of a typical ANK structure (Sedgwick and Smerdon,
1999). Therefore, ANK1 and the C-terminal halves of ANK2
and ANK3 of K1L are likely to form a contiguous surface,
possibly for ligand binding. The substitution at ANK1 or the
C-terminal halves of ANK2 and ANK3 may impair viral
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some important protein factors. It is of low possibility that these
substitutions impair K1L's host-range function through indirect
effect on protein structure. This is especially the case for the
substitutions at C-terminal halves of ANK2 and ANK3, as both
S2C and S3C mutants expressed WT level of K1L proteins,
demonstrating that the substitutions had no deleterious effects
on K1L protein stability. The substitutions at ANK1 (S1N and
S1C) reduced K1L proteins level in both permissive and
nonpermissive cells. The reason for this reduction is unclear, but
a low K1L protein level does not necessarily cause the host-
range defect, as several other substitutions, including those at N-
terminal halves of ANK2 and ANK3 and C-terminal half of
ANK5 (S2N, S3N and S5C), also result in a lower level of K1L
proteins but had no adverse effect on viral replication in HeLa
cells.
The finding that phenylalanine 82 and serine 83 of ANK2 act
synergistically in supporting VV replication in HeLa cells
further supports the hypothesis that the N-terminal three K1L
ANKs function by interacting with some protein factors.
Phenylalanine 82 is the most important ANK2 residue in
terms of the host-range function, and its substitution signifi-
cantly reduced VV growth rate in HeLa cells. Phenylalanine is
frequently found at the binding free energy “hot spot” of
protein–protein interaction (Bogan and Thorn, 1998), as it can
participate in both π- and van der Waals interactions. The
substitution of a single phenylalanine at the protein binding sites
often greatly reduces binding affinity (Bogan and Thorn, 1998;
Clackson and Wells, 1995). Recently, the binding free energy
hot spot for the ANK protein GABPβ was mapped to three
spatially contiguous residues including the phenylalanine at
position 136 (Desrosiers and Peng, 2005). The substitution of
phenylalanine 136 alone decreased the affinity of GABPβ to its
ligand dramatically. It is possible that a similar situation exists
for K1L, and phenylalanine 82 may be part of the binding free
energy hot spot for K1L. The optimal binding of K1L to its
ligand may require both phenylalanine 82 and serine 83, as the
substitution of each residue only reduced the growth rate but the
substitution of both residues completely abolished viral
replication in HeLa cells.
The finding that more K1L ANK residues are required for
optimal VV replication in rabbit RK13 cell than in HeLa cells
reveals some interesting difference in host restriction by RK13
and human cell lines. Host restriction of VV was known to be
different in RK13 and human cells, as VV C7L can support viral
replication in many human cell lines but not in RK13 cells.
However, the cause for this difference is unclear. We found that
a large portion of K1L protein, although not required for VV
replication in HeLa cells, is required for optimal VV replication
in RK13 cells. This includes the N-terminal halves of ANK2
and ANK3, the entire ANK5 and the C-terminal non-ANK
sequence. The deletion or substitution mutations at these
regions (S2N, S3N, S5N, S5C and D7) did not affect VV
replication in HeLa cells but reduced or abolished viral
replication in RK13 cells. In addition, while the substitution
of phenylalanine 82 or serine 83 (S2C#5 and S2C#6) reduced
the growth rate of VV in HeLa cells, it completely abolishedviral replication in RK13 cells. Previously, Bradley RR and
Terajima M reported that the simultaneous substitution of six
conserved ANK residues (residues 96–101) at N-terminal half
of K1L ANK3 abolished VV replication in RK13 cells (Bradley
and Terajima, 2005). As they used a parental virus encoding
C7L to generate this mutant, it was not possible to assess the
effect of this mutation on K1L's function in human cells, where
C7L provides a redundant host-range function. The use of a
parental virus with neither K1L nor C7L for generating the K1L
mutants allowed us to uncover this cell-type-specific require-
ment of K1L ANKs for the host-range function. One possible
explanation for this phenomenon is that the target of the host-
range gene products may exist at a higher concentration in
RK13 cells than in HeLa cells, so a higher concentration of the
host-range gene products or a host-range gene product with a
higher affinity to the target is needed in RK13 cells to overcome
the host-range restriction. Some of the K1L mutants that
displayed different phenotypes in RK13 and HeLa cells (S2N,
S3N and S5C) expressed K1L proteins at a reduced level. The
low level of K1L proteins is sufficient for overcoming the host
restriction in HeLa cells, but it may not be sufficient to do the
same in RK13 cells. However, this explanation may not explain
the cell type-specific phenotypes of all K1L mutants, as S5N,
S2C#5 and S2C#6 mutations do not significantly reduce K1L
protein level in permissive cells. An alternative and probably
more interesting explanation is that there are more host factors
in RK13 cells than in HeLa cells for restricting VV replication,
so some K1L mutants are only defective at replicating in RK13
cells because of a defect in targeting RK13 cell-specific host
restriction factors. It is possible that C7L is unable to support
viral replication in RK13 cells due to its inability to interact with
these RK13 cell-specific host factors.
It is also intriguing to find that not all K1L mutations either
maintain or completely disrupt the host-range function. The
substitution of phenylalanine 82 or serine 83 reduced the growth
rate of VV in HeLa cells to two different levels, and the deletion
of C-terminal non-ANK sequence reduced specifically the
growth rate of VV in RK13 cells. These data demonstrated that
the growth rate of VV in different cell types can be modulated
by genetic engineering of the host-range genes. Host-range-
restricted VVs including NYVAC and MVA have been used as
vaccine vectors for cancer and other infectious diseases. The
lost of the host-range genes and the resulted inability to replicate
productively in mammalian hosts make them very safe even in
immuno-compromised hosts. However, they tend to have a
decreased immunogenicity than replication-competent VV
(Earl et al., 2004; Kaufmann and McMichael, 2005; Spearman,
2006). In early clinical trials, MVA-based HIV vaccine has been
proven safe, but weakly immunogenic (Kaufmann and
McMichael, 2005). A combination of a DNA “prime” and
MVA “boost” induced HIV-specific CD8 T-cell responses in
approximately 10–20% of a total of 205 volunteers participat-
ing in multiple phase I and II studies in the UK and Kenya
(Cohen, 2004). One possible reason for the weak immunoge-
nicity is that the viral vector may be too attenuated, with little or
no proliferation after infection (Kaufmann and McMichael,
2005). Our data suggest that genetic engineering of the host-
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VV vectors in mammalian hosts to achieve an optimal balance
between safety and immunogenicity.
The comprehensive structure–function analysis of the K1L
gene also allowed us to explore the significance of the
interaction between K1L and ACAP2 in terms of the host-
range function. The rabbit homologue of human ACAP2 was
the only known host factor that interacts with K1L (Bradley and
Terajima, 2005). We showed that K1L was able to interact
specifically with ACAP2, demonstrating that this interaction is
not limited to rabbit cells. We also demonstrated that ACAP2
binding is not sufficient for the host-range function, as the
substitution of both phenylalanine 82 and serine 83 (S2C#2)
abolished the host-range function but had no impact on ACAP2
binding. This offers another piece of evidence that the S2C#2
substitution did not impair the host-range function through
indirect effect on K1L protein structure. The substitutions at
ANK4 disrupted K1L's ability to precipitate ACAP2 but had no
adverse effect on VV replication. It remains possible that the
mutated K1L proteins could interact with ACAP2 transiently or
at a reduced affinity to provide the host-range function.
Alternatively, K1L may interact with ACAP2 to affect some




VERO (ATCC CCL-81) and RK-13 (ATCC CCL-37) cells
were cultured in minimum essential medium with Earle's
balanced salts (Invitrogen) supplemented with 10% fetal bovine
serum (FBS). HeLa 229 (ATCC CCL-2.1) and HEK293T cells
were cultured in Dulbecco's modified Eagle's medium
(Invitrogen) with 10% FBS. vTF7.3 (ATCC VR-2153) and all
other recombinant viruses were propagated on VERO cells.
Plasmids construction
The transfer plasmid pYW31, which encodes the green
fluorescence protein (GFP) under the control of VV P11
promoter and the Escherichia coli xanthine-guanine phosphor-
ibosyltransferase (gpt) under the control of VV P7.5 promoter,
was constructed by excising the cassette containing the β-
glucuronidase (gus) gene from pBSgptgus (Ishii and Moss,
2001) with restriction enzymes BamHI and NotI and replacing
it with the GFP cassette from pFFH6RΔ (Da Fonseca and Moss,
2003).
The transfer plasmid pK1L-V5-GFP, which contains the left
and right flanking sequences of K1L and the coding sequence for
K1L with a C-terminal V5 epitope tag and the GFP under the
control of VV late stage promoter P11, was constructed as the
following. The coding sequence for K1L with a C-terminal V5
epitope tag and approximately 300 bps of the left and right K1L
flanking sequences were assembled by recombinant PCR with
VV genomic DNA as the template and the primer pairs K1L#4
(5′-TATAAAATGTTTCAGAATGC-3′) and V5-K1L (5′-GAC-CGAGGAGAGGGTTAGGGATAGGCTTACCGTTTTTCTT-
TACACAATTG-3′), K1L#3 (5′-ACTCACCAATAATAGTAGAA-
3′) and K1L-Left-V5 (5′-CCCTAACCCTCTCCTCGGT-
CTCGATTCTACGTAATTAGATTCTCCCACAT-3′). The
underlined sequences denote those sequences that were added
to the primers for appending the V5 coding sequence to 3′ end of
the K1L gene. The italicized sequences indicate the SnaBI site
present at the end of the V5 coding sequence. The recombinant
PCR product was TA-cloned into pCR2.1 vector (Invitrogen),
yielding pLJ5. A cassette containing GFP was excised from
pYW31, made blunt end with T4 DNA polymerase, and ligated
into a single HpaI site located immediate 3′ to the K1L coding
sequence in pLJ5, yielding pK1L-V5-GFP.
The transfer plasmid pLJ12 for deleting the K1L gene from
VV was constructed as the following. The entire K1L coding
sequences were removed from pLJ5 with BglII and SnaBI
digestion followed by re-circularization of the remaining
plasmid, yielding pLJ7. The remaining left and right flanking
sequences of K1L in pLJ7 were then excised with restriction
enzymes XhoI and EcoRV and ligated into the same sites of
pYW31, yielding pLJ12.
The transfer plasmid pMX35 for deleting the C7L gene from
VV was constructed as the following. The coding sequence for
C7L and approximately 300 bps of the left and right C7L
flanking sequences were amplified from VV genomic DNA
with the primer pairs C7L#3 (5′-ATAAACGGAGCACAC-
CATTTAG-3′) and C7L#4 (5′-GTCGTAGATATTAA-
CAAAGGTTGTG-3′), and TA-cloned into pSTBlue-1 vector
(Novagen), yielding pMX32. The C7L coding sequences in
pMX32 were then removed with SpeI and NcoI digestion
followed by re-circularization of the remaining plasmid,
yielding pMX34. The cassette containing GFP and gpt was
excised from pYW31 with SacI and HindIII digestion and
ligated into the same sites of pMX34, yielding pMX35.
The plasmids for making K1L mutant VVs were all
derived from pK1L-V5-GFP with recombinant PCR tech-
niques. For each K1L mutation, a pair of mutagenesis
primers with complementary sequence was used together
with either primer K1L#3 or K1L#4 in two separate PCR
reactions. The resulted PCR products were then assembled
together by recombinant PCR and substituted into the K1L
coding sequence of pK1L-V5-GFP using the SspI and MfeI
sites. For substituting K1L ANKs with the synthetic ANK
repeat, the coding sequence for the synthetic ANK was
first assembled by PCR with six overlapping oligodeox-
ynucleotides, which were designed with DNAWorks 2.4
(Hoover and Lubkowski, 2002). The assembled sequence
was then used as one of the template in recombinant PCR
reaction to substitute the coding sequence for K1L ANK in
pK1L-V5-GFP.
The mammalian expression vectors for Flag-tagged ACAP1
and ACAP2 were a kind gift of Dr. Paul A. Randazzoa (Jackson
et al., 2000). The mammalian expression vector for V5-tagged
K1L was generated by PCR with pK1L-V5-GFP as the template
and with primers incorporating NheI and BamHI sites. The
PCR product was digested with NheI and BamHI and ligated
into the same sites of pcDNA3.1 (Invitrogen).
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by DNA sequencing with an ABI 3100 Genetic Analyzer.
Recombinant virus construction
All recombinant viruses were derived from vTF7.3, which
contains the bacteriophage T7 RNA polymerase gene inserted
into the nonessential thymidine kinase locus (Fuerst et al.,
1986). vTF7.3 was originally chosen to allow the over-
expression of K1L proteins in infected cells that were also
transfected with a plasmid encoding K1L under the control of
T7 promoter, but, in this study, vTF7.3 functioned essentially
the same as the wild-type WR virus. vK1L−C7L− was
constructed by sequentially removing the K1L and C7L genes
from vTF7.3 (Fig. 1). An intermediate virus named vK1L− was
first constructed by deleting the K1L gene from vTF7.3 with the
transient dominant selection method, essentially as described
previously (Falkner and Moss, 1990). Briefly, the transfer
plasmid pLJ12 was transfected into VERO cells infected with
vTF7.3. The cell lysates were applied to VERO cells that were
treated with mycophenolic acid (MPA), xanthine and hypoxan-
thine at concentrations of 25, 250 and 15 μg/ml, respectively.
Recombinant viruses expressing GFP were picked under the
fluorescence microscope and purified by three rounds of plaque
purification. Subsequently, the recombinant viruses were
propagated in the absence of MPA, and GFP-negative plaques
containing double-crossover mutants were purified by three
additional rounds of plaque purification. The deletion of K1L in
the recombinant virus was confirmed by PCR amplification of
the K1L region of the virus. Subsequently, the transfer plasmid
pMX35 was used to delete C7L gene from vK1L− with the
transient dominant selection method to make the final
vK1L−C7L− virus, essentially the same as described for the
construction of vK1L− virus.
vK1L-WT and various K1L mutants were constructed by
homologous recombination of vK1L−C7L− with pK1L-V5-
GFP or derivatives of pK1L-V5-GFP using the standard method
(Moss and Earl, 1998). Briefly, pK1L-V5-GFP or its derivatives
were transfected into VERO cells that were infected with
vK1L−C7L−. Recombinant viruses encoding GFP and the K1L
with a V5 epitope tag were picked under the fluorescence
microscope and purified by four rounds of plaque purification
on VERO cells.
Grow curve analysis of K1L mutants
RK13 or HeLa cells in 12-well plates were incubated with
0.01 or 5 PFU per cell of different K1L mutants for 2 h at
room temperature. Following adsorption, the cells were
washed twice with phosphate-buffered saline (PBS) and
moved to 37 °C incubator to initiate viral entry and replication.
The cells were harvest at 0, 12 and 48 hpi. The viral titers in
the cell lysates were determined by plaque assays on VERO
cells. The results were confirmed by repeating the same ex-
periment at least one time. Infected cells expressing GFP were
also visualized under an inverted fluorescence microscopy
using a 10× objective and photographed with a digital camera(Kodak). The exposure time was kept constant when photo-
graphing different samples.
Immunoprecipitation and Western blot analysis
For co-immunoprecipitation with HEK 293T cells, the cells
in 6-well plate were transfected with 2 μg of the mammalian
expression plasmid for K1L-V5 and 2 μg of the mammalian
expression plasmid for ACAP1-Flag or ACAP2-Flag. 48 h after
transfection, the cells were harvested, washed 1 time with cold
PBS, incubated with lysis buffer (M-PER; Pierce) supplemen-
ted with protease inhibitor cocktail tablets (Roche Molecular
Biochemicals) for 10 min on ice and centrifuged at 16,000×g for
5 min. The cleared cell lysates were then subject to
immunoprecipitation and Western blot analysis. For Western
blot analysis, the same amount of lysates, as measured by
Bradford protein assay, were solubilized in sodium dodecyl
sulfate (SDS) sample buffer, resolved by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE), transferred to nitrocellulose
membranes and blocked with Tris-buffered saline supplemented
with 5% nonfat dried milk and 0.05% Tween-20 for 1 h at room
temperature. Subsequently, membranes were incubated with the
monoclonal antibody against V5 or Flag (Sigma-Aldrich),
washed, incubated with horseradish peroxidase-conjugated
secondary antibodies (Amersham) and analyzed with chemilu-
minescence reagents (Pierce). The chemiluminescence images
were captured with a CCD camera in a ChemiDoc system
(Biorad). For immunoprecipitation, the cleared cell lysates were
rotated with 50 μl of 50% (vol/vol) anti-V5-agarose beads or
anti-Flag-agarose beads (Sigma-Aldrich) overnight at 4°C. The
beads were washed five times with wash buffer (0.1% (w/v)
Triton X-100, 50 mM Tris, pH 7.4, 300 mM NaCl, 5 mM
EDTA) and resuspended in SDS sample buffer. Samples were
incubated at 95 °C for 5 min and resolved by SDS-PAGE. The
presence of ACAP1-Flag or ACAP2-Flag was examined by
Western blot analysis with the anti-Flag antibody. The same
membrane was then incubated with the Restore Western Blot
Stripping Buffer (Pierce) for 20 min and Western blot analysis
was performed again with the anti-V5 antibody.
For co-immunoprecipitation with infected HeLa cells, the
cells were harvested 8 h post-infection (hpi) and immunopre-
cipitated with anti-V5-agarose bead similarly as described
above. The presence of ACAP2 in the precipitate was examined
by Western blot analysis with a monoclonal antibody against
ACAP2 (BD Transduction Laboratories; clone 24).
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